Journal Article

Use of Selective Serotonin Reuptake Inhibitors and the Risk of Breast Cancer

Patricia F. Coogan, Julie R. Palmer, Brian L. Strom and Lynn Rosenberg

in American Journal of Epidemiology

Published on behalf of Johns Hopkins Bloomberg School of Public Health

Volume 162, issue 9, pages 835-838
Published in print November 2005 | ISSN: 0002-9262
Published online September 2005 | e-ISSN: 1476-6256 | DOI: http://dx.doi.org/10.1093/aje/kwi301
Use of Selective Serotonin Reuptake Inhibitors and the Risk of Breast Cancer

Show Summary Details

Preview

Selective serotonin reuptake inhibitors (SSRIs) were introduced in 1987 and, by 1997, were prescribed to 58% of Americans receiving outpatient treatment for depression. In 1992, a study reported that one of the SSRIs, fluoxetine, accelerated the growth of mammary tumors in rodents. By use of data from 1988 to 2002 from their hospital-based, case-control surveillance study, the authors examined the relation between use of SSRIs and risk of breast cancer. Nurse interviewers administered standard questionnaires to patients admitted to hospitals in three US centers to obtain information on demographic, medical, and lifestyle factors and to elicit a history of drug use, including antidepressants. Cases comprised 2,138 women with primary invasive breast cancer, and controls comprised 2,858 women admitted with nonmalignant diagnoses unrelated to SSRI use. The authors used multivariate conditional logistic regression models to estimate odds ratios for breast cancer among regular users of SSRIs compared with nonusers. The odds ratio was 1.1 (95% confidence interval: 0.8, 1.7) for regular use of SSRIs and 0.7 (95% confidence interval: 0.4, 1.5) for use of 4 or more years. Odds ratios were not elevated for any specific SSRI. These data provide some assurance that the use of SSRIs does not increase the risk of breast cancer.

Keywords: antidepressive agents; breast neoplasms; case-control studies; pharmacoepidemiology; CI, confidence interval; OR, odds ratio; SSRI, selective serotonin reuptake inhibitor

Journal Article.  2373 words. 

Subjects: Public Health and Epidemiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.